TNFRSF8 and Hodgkins lymphoma: CD30 expression is a characteristic pathologic feature of eIMS,8,10,25–28 which represents a potential therapeutic target using the CD30-targeted antibody–drug conjugate brentuximab vedotin (BV).29 BV comprises a monoclonal CD30 antibody, conjugated to the antimitotic agent monomethyl auristatin-E (MMAE),29 and is currently used in the treatment of patients with Hodgkin's lymphoma and ALCL.29–31 We hypothesised that BV or a combination of BV and ALKi may be effective in treating eIMS.